Louis Lehot on Biotech IPOs – 'Biotech could have a great fourth quarter'
September 4, 2024
Bloomberg Law
Foley & Lardner LLP partner Louis Lehot offered insight on the biotech industry’s upcoming initial public offerings in the Bloomberg Law article, “Biotech IPO Hopefuls Ready Burst of Debuts After Rough Stretch.”
“Biotech could have a great fourth quarter, we have a great pipeline,” Lehot commented, as several biotech companies look to reignite the sector with upcoming IPOs. “Biotech IPOs are here and ready to put money to work.”
(Subscription required)
People
Related News
September 17, 2026
In the News
Foley Featured in Law.com for Guiding Kontoor Brands in Sale of Lee®
Foley & Lardner LLP partner Bryan Schultz is featured for leading the Foley deal team which advised Kontoor Brands in the sale of its Lee® business in Law.com's “How the Deal Got Done” series.
September 15, 2026
In the News
David Rosen Shares Insights on FDA Efforts to Accelerate Human Clinical Trials
Foley & Lardner LLP partner David Rosen shared insights in the recent Law360 article, “FDA Seeks Applications For Project To Speed Up Human Trials,” on the FDA's pilot program pairing pharmaceutical companies with research institutions to accelerate human clinical trials.
September 15, 2026
In the News
Scott Ellis Addresses Cost Pressures Driven by Data Center Demand
Foley & Lardner LLP partner Scott Ellis was quoted in Politico’s recent article on the rising costs of building the energy infrastructure needed to support growing data center demand.